Neutropenia is the most frequent side effect of commercially available myelosuppressive drugs and its most significant complication is febrile neutropenia. It is associated with increased hospital admissions and higher probability of death. Prophylaxis with the administration of granulocyte colony-stimulating factor can prevent neutropenia caused by anticancer drugs. The correct administration of these drugs and the management of febrile neutropenia are extremely important in the treatment of patients with cancer.
CaggianoVWeissRVRickertTS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer2005; 103: 1916–1924.
3.
KudererNMDaleDCCrawfordJ, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006; 106: 2258–2266.
4.
LymanGHMichelsSLReynoldsMW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer2010; 116: 5555–5563.
5.
von MinckwitzGKümmelSdu BoisA, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer: results from the GEPARTRIO study. Ann Oncol2008; 19: 292–298.
6.
YongWChenLLiuF, et al. Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis. Sci Rep2019; 9: 15374.
Italian Medical Oncology Association (AIOM). Methodo-logical manual, www.aiom.it (2015, accessed 21 February 2019).
9.
Scottish Intercollegiate Guidelines Network, https://www.sign.ac.uk (2019, accessed 21 February 2019).
10.
FreifeldAGBowEJSepkowitzKA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis2011; 52: e56–e93.
KlasterskyJde NauroisJRolstonK, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guideline. Ann Oncol2016; 27 (suppl 5): v111–v118.
13.
Trillet-LenoirVGreenJManegoldC, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer1993; 29A: 319–324.
14.
Timmer-BonteJNAdangEMSmitHJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibodies in small-cell lung cancer. J Clin Oncol2006; 24: 2991–2997.
15.
GreenMDKoelblHBaselgaJ, et al. International Pegfilgrastim 749 Study Group: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol2003; 14: 29–35.
16.
BondarenkoIGladkovOAElsaesserR, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer2013; 13: 386.
17.
VogelCLWojtukiewiczMZCarrollRR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol2005; 23: 1178–1184.
18.
RennerPMilazzoSLiuJP, et al. Primary prophylactic colony-stimuleting factors for the prevention of chemoptherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev2012; 10: CD007913.
19.
LymanGHDaleDCCulakovaE, et al. The impact of the granulocyte colony stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trias. Ann Oncol2013; 24: 2475–2484.
20.
Timmer-BonteJNde BooTMSmitHJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol2005; 23: 7974–7984.
21.
HaimNShulmanKGoldbergH, et al. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol2005; 22: 229–232.
22.
ChouaidCBassinetLFuhrmanC, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol1998; 16: 2700–2707.
23.
KohlerE, et al. Lipegfilgrastim: a long-acting, once- per-cycle filgrastim: pharmacokinetics and pharmacodynamics in healthy volunteers. Support Care Cancer2012; Abstract 997.
24.
BiganzoliLUntchMSkacelT, et al. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol2004; 31 (Suppl 8): 27–34.
25.
HolmesFAO’ShaughnessyJAVukeljaS, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol2002; 20: 727–731.
26.
KudererNMDaleDCCrawfordJ, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol2007; 25: 3158–3167.
27.
ParkJWMehrotraBBarnettBO, et al. The Sweet syndrome during treatment with granulocyte colony stimulating factor. Ann Intern Med1992; 116: 996–998.
28.
SmithREBryantJDeCillisA, et al. Acute myeloid leukaemia and myelodisplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol2003; 21: 1195–1204.
29.
KaushanskyK.Lineage-specific haematopoietic growth factors. N Engl J Med2006; 354: 2034–2045.
30.
LymanGHYauLNakovR, et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol2018; 29: 1903–1910.
31.
SmithTJBohlkeKLymanGH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol2015; 33: 3199–3212.
32.
National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2019.
33.
AaproMSBohliusJCameronDA, et al. European Organisation for Research and Treatment of Cancer: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disordrs and solid tumors. Eur J Cancer Jan 2011; p. 8-32. ;47(1):8–32.
34.
OzerHArmitageJOBennettCL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines: American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol2000; 18: 3558–3585.
35.
CrawfordJAllenJArmitageJ, et al. Myeloid growth factors. J Natl Compr Cancer Netw2011; 9: 914–932.
36.
BerghmansTPaesmansMLafitteJJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer2002; 10: 181–188.
37.
HartmannLCTschetterLKHabermannTM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med1997; 336: 1776–1780.
38.
ClarkOALymanGHCastroAA, et al. Colony-stimulating factors for chemotherapy febrile neutropenia: a mata-analysis of randomized controlled trials. J Clin Oncol2005; 23: 4198–4214.
39.
MhaskarRClarkOALymanG, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev2014; 10: CD003039.
40.
HughesWTArmstrongDBodeyGP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis2002; 34: 730–751.
41.
KudererNMDaleDCCrawfordJ, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006; 106: 2258–2266.
42.
ChaoCPageJHYangSJ, et al. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol2014; 25: 1821–1829.
43.
CarlosDVTimotheadouEGalaniE, et al. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology2009; 77: 107–112.
44.
PapaldoPLopezMMarollaP, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol2005; 23: 6908–6918.
45.
WeyckerDHackettJEdelsbergJS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?Ann Pharmacother2006; 40: 402–407.
46.
PhillipsJRitterSStarnerCI, et al. Filgrastim (Neupogen) and pegfilgrastim (Neulasta): cost analysis and utilization management opportunity assessment. Minneapolis: Blue Cross and Blue Shield of Minnesota; 2012.
47.
WeyckerDBarronREdelsbergJ, et al. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res2014; 14: 189.
48.
MitchellSLiXWoodsM, et al.Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract2016; 22: 702–716.
49.
CornesPGasconPChanS, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther2018; 35: 1830.
AaproMBocciaRLeonardR, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer2017; 25: 3295–3304.
52.
LinkHKerkmannMHoltmannL, et al. G-CSF guideline adherence in germany, an update with a retrospective and representative sample survey. Support Care Cancer2019; 27: 1459–1469.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
